-
Detailed Analysis
Download Detailed Report Add to Watchlist
Values as of: 2021-02-28
Values as of: 2021-02-28
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors or T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. Its products pipeline includes ADI-001, which is in Phase 1 clinical study to treat non-Hodgkin's lymphoma; and ADI-002 that is in Phase 1 clinical study for the treatment of hepatocellular carcinoma and other solid tumors. The company is based in Menlo Park, California. Address: 200 Constitution Drive, Menlo Park, CA, United States, 94025
Company Website : http://www.adicetbio.com
Address : 200 Constitution Drive, Menlo Park, CA, United States, 94025
Fiscal Year End : June
Currency: USD
Country : USA
Beta : 2.01
52 Week High : 21.40
Short Ratio : 1.10
52 Week Low : 6.02
Shorted Shares : 158,231
200 Day Moving Average : 13.66
Shorted Shares Previous Month : 141,748
50 Day Moving Average : 14.39
Shares Held By Insiders : 147.25%
Short Percentage : 1.00%
Shares Held by Institutions : 47.07%
Symbol | Name | Price(Change) | Market Cap | Price / Earning Ratio | EV/EBITDA |
---|---|---|---|---|---|
LGCY | Legacy Reserves Inc |
N/A |
USD61,525,874.67B | 1.10 | 5.30 |
FTD | FTD Companies, Inc |
N/A |
USD28,725,913.80B | N/A | N/A |
KEYW | The KeyW Holding Corporation |
N/A |
USD24,651,104.38B | 166.80 | 24.48 |
SNHY | Helios Technologies, Inc |
N/A |
USD17,848,852.22B | 1,000,000.00 | N/A |
QTNA | Quantenna Communications, Inc |
N/A |
USD8,997,243.52B | 175.07 | 79.98 |
INSY | INSYS Therapeutics, Inc |
N/A |
USD4,995,459.82B | 115.90 | N/A |
CHKE | Apex Global Brands Inc |
N/A |
USD384,202.91B | 17.30 | N/A |
AMCN | AirNet Technology Inc |
N/A |
USD308,457.30B | 1.00 | N/A |
PDVW | pdvWireless, Inc |
N/A |
USD95,944.74B | N/A | N/A |
AIPT | Predictive Oncology Inc |
N/A |
USD38,513.36B | N/A | N/A |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|
N/A
Market Performance vs. Industry/Classification (Other) |
Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 8.97% | 56% | F | 53% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 8.97% | 55% | F | 53% | F | ||
Trailing 12 Months | |||||||
Capital Gain | 11,282.90% | 99% | A+ | 100% | A+ | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 11,282.90% | 99% | A+ | 100% | A+ | ||
Trailing 5 Years | |||||||
Capital Gain | -30.16% | 14% | F | 16% | F | ||
Dividend Return | 2.71% | 11% | F | 4% | F | ||
Total Return | -27.44% | 14% | F | 15% | F | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 1,050.11% | 96% | A | 99% | A+ | ||
Dividend Return | 0.72% | 14% | F | 18% | F | ||
Total Return | 1,050.82% | 96% | A | 99% | A+ | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 3,164.71% | 5% | F | 1% | F | ||
Risk Adjusted Return | 33.20% | 56% | F | 57% | F | ||
Market Capitalization | 0.46B | 48% | F | 49% | F |
Letter Grade | Percentage | Letter Grade | Percentage | Letter Grade | Percentage |
A+ | 97%-100% | A | 93%-96% | A- | 90%-92% |
B+ | 87%-89% | B | 83%-86% | B- | 80%-82% |
C+ | 77%-79% | C | 73%-76% | C- | 70%-72% |
D+ | 67%-69% | D | 63%-66% | D- | 60%-62% |
F | 0%-59% |
Ratio vs. Industry/Classification (Other) |
Ratio vs. Market |
||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
Market Value | |||||||
Price / Earning Ratio | 39.60 | 14% | F | 28% | F | ||
Price/Book Ratio | N/A | N/A | N/A | N/A | N/A | ||
Price / Cash Flow Ratio | -16.61 | 79% | C+ | 78% | C+ | ||
EV/EBITDA | N/A | N/A | N/A | N/A | N/A | ||
Management Effectiveness | |||||||
Return on Equity | N/A | N/A | N/A | N/A | N/A | ||
Return on Invested Capital | -209.25% | 9% | F | 4% | F | ||
Return on Assets | N/A | N/A | N/A | N/A | N/A | ||
Debt to Equity Ratio | N/A | N/A | N/A | N/A | N/A | ||
Technical Ratios | |||||||
Short Ratio | 1.10 | 71% | C- | 64% | D | ||
Short Percent | N/A | N/A | N/A | N/A | N/A | ||
Beta | 2.01 | 22% | F | 14% | F |
Letter Grade | Percentage | Letter Grade | Percentage | Letter Grade | Percentage |
A+ | 97%-100% | A | 93%-96% | A- | 90%-92% |
B+ | 97%-89% | B | 83%-86% | B- | 80%-82% |
C+ | 77%-79% | C | 73%-76% | C- | 70%-72% |
D+ | 67%-69% | D | 63%-66% | D- | 60%-62% |
F | 0%-59% |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company has under performed its peers on annual average total returns in the past 5 years.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company had negative total cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector